Immunotherapy with blinatumomab improves the chances of survival in very rare childhood blood cancer

Federal Joint Committee (G-BA)

20 January 2022 - The Federal Joint Committee (G-BA) today classified the additional benefit of the active ingredient blinatumomab as significant for a new, very rare area of ​​application. 

It is only the second time that he has awarded this highest category of an additional benefit to an orphan drug. 

The results of a randomised, controlled and thus meaningful approval trial have shown that blinatumomab as monotherapy in children with a first relapse of a specific form of acute lymphatic leukaemia has very clear advantages compared to intensive chemotherapy.

Read G-BA press release [German]

Michael Wonder

Posted by:

Michael Wonder